Breaking News

Financial Report: Parexel

By Gil Roth | January 30, 2014

Service revenues rise across the board, with 30% bump for Perceptive Informatics unit

Financial Report: Parexel 2Q14

2Q Revenues: $574 million (+19%)

2Q Earnings: $28 million (+33%)

HY Revenues: $1.1 billion (+17%)

HY Earnings: $54 million (+49%)

Comments: Service revenues in 2Q14 grew 15% to $487 million, with recent acquisitions contributing $14 million to that pool. In the quarter, Clinical Research Services accounted for $364 million (+14%), Consulting and Medical Communications were $56 million (+13%), and the Perceptive Informatics group added $68 million (+30%). Backlog at the end of the quarter was $4.8 billion (+6% year-over-year). The reported backlog included gross new business wins in the quarter of $836 million, cancellations of $181.4 million, and a positive impact from foreign exchange rates of $11.1 million. The net book-to-bill ratio was 1.34 in the quarter.

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research